MBHB Partner Kevin Noonan Comments on Takeda Antitrust Verdict in Bloomberg Law

In Bloomberg Law, MBHB Partner Kevin Noonan shares his perspective on the $885 million antitrust verdict against Takeda Pharmaceuticals in a reverse-payment case. He argues that while branded and generic drugmakers will closely examine their agreements in light of this decision, the verdict is unlikely to fundamentally alter the industry’s approach to generic settlements. Read the full article here.